SCHEMBL24936191

SCHEMBL24936191

COc1ccnc(OCCCNC(=O)OC(C)(C)C)c1C(=O)/C=C/N(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.46
CA12 O43570 5/20 0.41
CA1 P00915 5/20 0.41
CA2 P00918 5/20 0.41
CA9 Q16790 5/20 0.41
DRD2 P14416 5/20 0.39
AXL P30530 2/20 0.39
DYRK1A Q13627 1/20 0.38
CYP1A1 P04798 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2B6 P20813 1/20 0.37
CYP2C19 P33261 1/20 0.37
CYP3A43 Q9HB55 1/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
ATM Q13315 1/20 0.36
PDPK1 O15530 1/20 0.36
CCNB2 O95067 1/20 0.36
PRKCB P05771 1/20 0.36
CDK1 P06493 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24936245 0.85 STK17B (0.41) KCNH2CA12CA1CA2CA9
SCHEMBL28527177 0.85 DRD2 (0.45) CA12CA1CA2CA9DRD2
SCHEMBL19007375 0.85 DRD2 (0.45) CA12CA1CA2CA9DRD2
SCHEMBL24936189 0.84 KCNH2 (0.50) KCNH2CA12CA1CA2CA9
SCHEMBL30522714 0.84 KCNH2 (0.50) KCNH2CA12CA1CA2CA9
SCHEMBL29827443 0.83 KCNH2 (0.46) KCNH2CA12CA1CA2CA9
SCHEMBL24485511 0.79 KCNH2 (0.52) KCNH2CA12CA1CA2CA9
SCHEMBL29827219 0.73 KCNH2 (0.52) KCNH2CA12CA1CA2CA9
SCHEMBL24936185 0.73 KCNH2 (0.52) KCNH2CA12CA1CA2CA9
SCHEMBL29827348 0.72 STK17B (0.41) KCNH2CA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11564920-B2 5-heteroaryl-1H-pyrazol-3-amine derivative Sumitomo Pharma Co., Ltd. (JP) 2023-01-31 US disclosed
US-20230025065-A1 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2023-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11564920-B2 5-heteroaryl-1H-pyrazol-3-amine derivative CHEK1, CHEK2, RB1 KCNH2 2700/4885CA12 4344/4885CA1 4144/4885
US-20230025065-A1 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE CHEK1, CHEK2, RB1 KCNH2 2700/4885CA12 4344/4885CA1 4144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.